

INVIVO THERAPEUTICS HOLDINGS CORP.

Form 8-K

June 01, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 or 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**May 30, 2012**

**Date of Report (Date of earliest event reported)**

**INVIVO THERAPEUTICS HOLDINGS CORP.**

**(Exact Name of Registrant as Specified in Charter)**

NEVADA

000-52089

36-4528166

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)  
**One Broadway, 14<sup>th</sup> Floor**

(IRS Employer  
Identification No.)

**Cambridge, Massachusetts 02142**

(Address of Principal Executive Offices) (Zip Code)

**(617) 475-1520**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On May 30, 2012, the 2012 Annual Meeting of Shareholders of InVivo Therapeutics Holdings Corp. (the Company) was held. The following matters were submitted to the stockholders at the meeting, all of which were approved:

the election of one Class I director to hold office for a three-year term ending at the annual meeting of shareholders in 2015;

the approval of an amendment to the Company's 2010 Equity Incentive Plan to increase the number of shares of common stock available for issuance thereunder from 3,500,000 shares to 6,500,000 shares; and

the ratification of the appointment of ratify the appointment of Wolf & Company, P.C., an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2012.

The number of votes for and against and the number of abstentions and non-votes with respect to each matter are set forth below.

***Election of Class I Director***

Nominee	For Votes	Withheld Votes	Broker Non-Votes
Dr. Richard J. Roberts	29,886,433	1,925,426	13,508,731

***Approval of Amendment to 2010 Equity Incentive Plan***

For	Against	Abstained	Broker Non-Votes
28,902,523	2,633,986	275,350	13,508,731

***Ratification of Appointment of Wolf & Company, P.C. as independent auditor***

For	Against	Abstained	Broker Non-Votes
44,673,550	522,656	124,384	0

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVO THERAPEUTICS HOLDINGS CORP.

Date: June 1, 2012

By: /s/ Frank M. Reynolds  
Frank M. Reynolds  
Chief Executive Officer